Table 2.
Expression of the biomarkers in the two Cohorts.
| Nivolumab Cohort n (%) | |||||||
| Biomarkers | <1% | 1%–9% | 10%–49% | ≥50% | ND | Positive Total | Negative Total |
| PD-L1 | 38 (82.6) | 4 (8.7) | 2 (4.3) | 1 (2.2) | 1 (2.2) | 7 (15.6) | 38 (84.4) |
| PD-L2 | 38 (82.6) | 2 (4.3) | 5 (10.9) | 1 (2.2) | 0 (0.0) | 8 (17.4) | 38 (82.6) |
| PD-1 | 13 (28.3) | 8 (17.4) | 5 (10.9) | 18 (39.1) | 2 (4.3) | 31 (70.5) | 13 (29.5) |
| B7-H3 | 40 (87.0) | 2 (4.3) | 3 (6.5) | 1 (2.2) | 0 (0.0) | 6 (13.0) | 40 (87.0) |
| B7-H4 | 29 (63.0) | 5 (10.9) | 4 (8.7) | 8 (17.4) | 0 (0.0) | 17 (27.0) | 29 (63.0) |
| Chemotherapy Cohort n (%) | |||||||
| Biomarkers | <1% | 1%–9% | 10%–49% | ≥50% | ND | Positive Total | Negative Total |
| PD-L1 | 21 (77.8) | 5 (18.5) | 1 (3.7) | 0 (0.0) | 0 (0.0) | 6 (22.2) | 21 (77.8) |
| B7-H4 1 | 12 (44.4) | 3 (11.1) | 3 (11.1) | 9 (33.3%) | 0 (0.0%) | 15 (55.6) | 12 (44.4) |
Expression of the potential immune-related biomarkers in the Nivolumab Cohort and in the Chemotherapy Cohort reported into each cut-off category; the evaluable samples from each cohort were then divided between positive (≥1%) and negative (<1%) expression. 1 Total = 99.9% due to approximation.